Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 103,184

Document Document Title
WO/2014/174834A1
Provided is a therapeutic agent for neurological disorder, said therapeutic agent directly acting on vascular barrier failure that depends on oxygen concentration. The therapeutic agent for neurological disorder comprises, as an active i...  
WO/2014/174564A1
The purpose of the present invention is to provide an adhesive patch drug formulation containing memantine or a pharmaceutically acceptable salt thereof, adhesive patch drug keeping sublimation of the memantine during manufacture may to ...  
WO/2014/176149A1
Andrographolide binds to GSK-3Beta, preventing changes in neuropathology in an Alzheimer's model, reducing Amyloid-Beta peptide levels, changing the ontogeny of hippocampus and cortex amyloid plaques, and reducing tau phosphorylation aro...  
WO/2014/170319A1
The invention refers to a combination comprising a Sigma ligand of general formula (I) and alpha-2-adrenergic agonist compound, a medicament comprising said active substance combination, and the use of said active substance combination f...  
WO/2014/171828A1
The present invention relates to food compositions comprising nutritional composition for use in the treatment or nutritional management of phenylketonuria or hyperphenylalaninemia or for preserving or improving brain function in PKU or ...  
WO/2014/172482A1
The invention is directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient.  
WO/2014/171542A1
The present invention provides a controlled-release solid drug formulation containing pioglitazone or a salt thereof as an active ingredient, and having exceptional sustained release properties. The controlled-release solid drug formulat...  
WO/2014/172266A1
Disclosed herein are methods and compositions related to therapeutic use of aminopyridines in patients with stroke-related impairments, in particular, in patients with sensorimotor impairments resulting from certain types of stroke.  
WO/2014/170494A1
The present invention relates to new tricyclic triazolic compounds of formula (I) having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprisin...  
WO/2014/172478A1
The aspects of the disclosed embodiments are directed to novel compounds, specifically, quaternary ammonium derivatives of tertiary amine containing opioid drug compounds such as hydrocodone, hydromorphone and oxycodone, formulations con...  
WO/2014/169833A1
Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7are as defined herein. Such compounds are contemplate...  
WO/2014/171781A1
The present invention relates to a composition including a Laurus nobilis leaf extract as an active ingredient, and particularly, to a composition for preventing or treating hangover including the Laurus nobilis leaf extract, a food comp...  
WO/2014/170902A1
The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4'-O-methylhonokiol for t...  
WO/2014/169832A1
Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related condi...  
WO/2014/171583A1
The present invention relates to a composition for preventing and/or treating a stroke or a degenerative brain disease comprising: at least two substances selected from the group consisting of egg yolk lecithin, glycerol, sodium oleate, ...  
WO/2014/171813A1
The present invention relates to food compositions comprising nutritional composition for use in the treatment of phenylketonuria or hyperphenylalaninemia or for preserving or improving brain function in PKU or hyperphenylalaninemia. The...  
WO/2014/169831A1
Provided herein are19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein, ⃜⃜, R1, R2, R3a, R3b, R4a, and R 4bare as defined herein, and A is a carbon bound substituted or unsubstitu...  
WO/2014/170343A1
The present invention relates to a composition comprising a depolarizing agent acting on a receptor expressed by the dopamine neurons of the substantia nigra, and a modulator of the nicotinic cholinergic pathway, wherein said receptor ex...  
WO/2014/171434A1
The present invention addresses the issue of providing an anti-Alzheimer's agent that uses an amyloid β-protein as the mechanism of action therefor but that is different from conventional mechanisms of action. This therapeutic agent for...  
WO/2014/170352A1
The present invention relates to nalmefene for use in the treatment of anxiety disorders. The present invention further relates to nalmefene for use in the treatment of patients with alcohol dependence who have a co-morbid anxiety disord...  
WO/2014/170353A1
The present invention relates to nalmefene for use in the treatment of sleep disorders. The present invention further relates to nalmefene for use in the treatment of patients with alcohol dependence who have a co-morbid sleep disorder. ...  
WO/2014/170521A1
The invention relates to the use of protein particles generated from recombinant pion protein (rPrP) subjected to a polymerisation process for the treatment and/or prevention of prion diseases. Such particles behave as an "attenuated" pr...  
WO/2014/170248A1
The present invention is directed to arylpyrrolopyridine derivatives of formula (A) (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease cancer.  
WO/2014/169836A1
Provided herein are 3,3-disubstituted19-nor-steroidal compounds according to Formula(I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditi...  
WO/2014/170706A1
The present invention relates to the use of compounds having a galloyl benzamide structure in the treatment and/or prevention of medical conditions mediated through c-Jun N-terminal kinases (JNKs) and to pharmaceutical compositions compr...  
WO/2014/170351A1
The present invention relates to nalmefene for use in the treatment of mood disorders. The present invention further relates to nalmefene for use in the treatment of patients with alcohol dependence who have a co-morbid mood disorder. Th...  
WO/2014/171532A1
[Problem] To provide an anti-human TWEAK antibody having superior activity as compared to conventional anti-human TWEAK antibodies, and a means for preventing or treating various diseases in which human TWEAK is involved in the pathogene...  
WO/2014/170892A1
The present invention provides compositions and methods for treating lysosomal storage disease characterized by elevation of RIP kinase in a subject in need thereof using at least one RIP kinase inhibitor.  
WO/2014/170900A1
Eph A receptor inhibitor peptides, and particularly Eph A4 receptor inhibitor peptides, are provided. The peptides comprise a sequence derived from the G-H loop of ephrin A4. Further, pharmaceutical compositions comprising said peptides ...  
WO/2014/171528A1
[Problem] To provide a compound of formula (I) that is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM). [Solution] The inventors studied a compound that has a dopamine D1 receptor positive allosteric modulating ac...  
WO/2014/170704A1
The invention relates to new morphine derivatives deuterated at the 7,8-position of the morphine ring, furthermore to a process for the preparation thereof, and to pharmaceutical compositions comprising them. The new deuterated morphine ...  
WO/2014/168925A1
Compositions comprising one or more opioids and one or more inhibitors of uridine diphosphate glucuronosyl transferases (UGTs) are provided. The inhibitors decrease the presystemic metabolism of the one or more opioids, thereby increasin...  
WO/2014/168262A1
The invention provides compound (I): wherein each symbol is as defined in the specification, having a tyrosine kinase inhibitory action on Trk receptors such as TrkA, TrkB, TrkC or other tyrosine kinase receptors such as Flt-3, which is ...  
WO/2014/166906A1
The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the prese...  
WO/2014/168727A1
The present invention relates to a fixed dosage unit, and methods for treating schizophrenia comprising administering the fixed dosage unit. More specifically, the present invention relates to a fixed dosage unit that reduces the inciden...  
WO/2014/168228A1
The purpose of the present invention is to provide a pregabalin-containing composition that can produce satisfactory drug efficacy through topical administration. This composition is characterized in that the composition is one for topic...  
WO/2014/168523A1
The present invention relates to novel biologically active compounds being dicarboxylic acid bisamide derivatives of general formula (I), or pharmaceutically acceptable salts thereof, which are capable of complexing or chelating metal io...  
WO/2014/167439A1
The present invention relates to modified release pharmaceutical compositions of topiramate or salts thereof. In particular, the present invention relates to modified release pharmaceutical compositions comprising at least two types of c...  
WO/2014/163150A1
Provided is a composition for internal use, which contains methylthioadenosine and is reduced in bitterness. This composition for internal use contains methylthioadenosine or a salt thereof (component (A)) and S-adenosylmethionine or a s...  
WO/2014/163210A1
A compound selected from the group consisting of compounds represented by the formulas below or pharmaceutically acceptable salt thereof is useful in PET imaging for AMPA receptor.  
WO/2014/163328A1
Provided in the present specification is a composition for brain activation, comprising ginseng berry extract as an active ingredient. The composition according to the present specification allows an increase in blood flow in the brain a...  
WO/2014/162195A1
Novel two-component formulations, procedures and methods for use in treating neuropathology incident to trauma are provided, Two-component formulations of the invention comprise biologically active forms of at least one neurosteroid or n...  
WO/2014/163402A1
The present invention relates to a composition which improves the quality of life of women by containing a ginseng berry extract as an active ingredient and, more specifically, to a composition which promotes the general psychological an...  
WO/2014/162276A1
The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek s...  
WO/2014/163643A1
This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and in...  
WO/2014/165701A1
Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptamine sub-receptor six (5-HT 6) receptor antagonists are provided for improving the cognition o...  
WO/2014/163147A1
The present invention provides a salt produced from at least one acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, malonic acid, maleic acid, tartaric acid, metha...  
WO/2014/163161A1
The present invention pertains to a compound indicated by formula (I), said compound being useful as a prophylactic or treatment agent for epilepsy and neurodegenerative diseases, etc. In the formula (I), each symbol is as defined in the...  
WO/2014/161095A1
Disclosed herein are human CRP40 fragments and polynucleotides encoding them. The CRP40 fragments and polynucleotides may be useful in the treatment of diseases associated with one or more of oxidative stress, mitochondrial dysfunction a...  
WO/2014/161037A1
The present invention relates to antibodies and antigen-binding fragments thereof that bind RYK, in particular human RYK and their use in regulating RYK-associated activities. Specifically there is provided an isolated monoclonal antibod...  

Matches 51 - 100 out of 103,184